Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. (3rd July 2021)

• Record Type: Journal Article
• Authors: Mishima, Saori; Shitara, Kohei
• Is Part Of: Expert opinion on biological therapy. Volume 21:Number 7(2021)
• Page Start: 825
• Page End: 830
• Publication Date: 2021-07-03
• Subjects: Trastuzumab deruxtecan (T-DXd) -- HER2 -- gastric cancer; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2021.1912007
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction : Trastuzumab deruxtecan (T-DXd) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate with a humanized anti-HER2 antibody, cleavable peptide-based linker, and topoisomerase I inhibitor payload. The phase II trial DESTINY-Gastric01 has demonstrated that T-DXd exhibits antitumor activity in patients with HER2-positive advanced gastric cancer (AGC) who had received at least two previous therapies, including trastuzumab. Area covered : T-DXd was approved for previously treated HER2-positive AGC in Japan. The US Food and Drug Administration also approved on 15 January 2021. In this article, we review the development of T-DXd, its pharmacology, and its safety profile in patients with HER2-positive AGC. Expert opinion : T-DXd has demonstrated a significantly higher objective response rate and a longer overall survival in HER2-positive AGC patients with two or more previous lines of systemic chemotherapy, including trastuzumab. Safety profile was acceptable. Currently, there are several ongoing clinical trials of T-DXd in combination with cytotoxic chemotherapy or an immune checkpoint inhibitor.